Cargando…
Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( )
BACKGROUND: Comprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SAR...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278222/ https://www.ncbi.nlm.nih.gov/pubmed/35749674 http://dx.doi.org/10.1093/cid/ciac399 |
_version_ | 1784746146845949952 |
---|---|
author | Oh, Djin Ye Hölzer, Martin Paraskevopoulou, Sofia Trofimova, Maria Hartkopf, Felix Budt, Matthias Wedde, Marianne Richard, Hugues Haldemann, Berit Domaszewska, Teresa Reiche, Janine Keeren, Kathrin Radonić, Aleksandar Ramos Calderón, Julia Patricia Smith, Maureen Rebecca Brinkmann, Annika Trappe, Kathrin Drechsel, Oliver Klaper, Kathleen Hein, Sascha Hildt, Eberhardt Haas, Walter Calvignac-Spencer, Sébastien Semmler, Torsten Dürrwald, Ralf Thürmer, Andrea Drosten, Christian Fuchs, Stephan Kröger, Stefan von Kleist, Max Wolff, Thorsten |
author_facet | Oh, Djin Ye Hölzer, Martin Paraskevopoulou, Sofia Trofimova, Maria Hartkopf, Felix Budt, Matthias Wedde, Marianne Richard, Hugues Haldemann, Berit Domaszewska, Teresa Reiche, Janine Keeren, Kathrin Radonić, Aleksandar Ramos Calderón, Julia Patricia Smith, Maureen Rebecca Brinkmann, Annika Trappe, Kathrin Drechsel, Oliver Klaper, Kathleen Hein, Sascha Hildt, Eberhardt Haas, Walter Calvignac-Spencer, Sébastien Semmler, Torsten Dürrwald, Ralf Thürmer, Andrea Drosten, Christian Fuchs, Stephan Kröger, Stefan von Kleist, Max Wolff, Thorsten |
author_sort | Oh, Djin Ye |
collection | PubMed |
description | BACKGROUND: Comprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern led to an expansion of genomic sequencing activities in Germany. METHODS: At Robert Koch Institute (RKI), the German National Institute of Public Health, we established the Integrated Molecular Surveillance for SARS-CoV-2 (IMS-SC2) network to perform SARS-CoV-2 genomic surveillance at the national scale, SARS-CoV-2–positive samples from laboratories distributed across Germany regularly undergo whole-genome sequencing at RKI. RESULTS: We report analyses of 3623 SARS-CoV-2 genomes collected between December 2020 and December 2021, of which 3282 were randomly sampled. All variants of concern were identified in the sequenced sample set, at ratios equivalent to those in the 100-fold larger German GISAID sequence dataset from the same time period. Phylogenetic analysis confirmed variant assignments. Multiple mutations of concern emerged during the observation period. To model vaccine effectiveness in vitro, we employed authentic-virus neutralization assays, confirming that both the Beta and Zeta variants are capable of immune evasion. The IMS-SC2 sequence dataset facilitated an estimate of the SARS-CoV-2 incidence based on genetic evolution rates. Together with modeled vaccine efficacies, Delta-specific incidence estimation indicated that the German vaccination campaign contributed substantially to a deceleration of the nascent German Delta wave. CONCLUSIONS: SARS-CoV-2 molecular and genomic surveillance may inform public health policies including vaccination strategies and enable a proactive approach to controlling coronavirus disease 2019 spread as the virus evolves. |
format | Online Article Text |
id | pubmed-9278222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92782222022-07-18 Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) Oh, Djin Ye Hölzer, Martin Paraskevopoulou, Sofia Trofimova, Maria Hartkopf, Felix Budt, Matthias Wedde, Marianne Richard, Hugues Haldemann, Berit Domaszewska, Teresa Reiche, Janine Keeren, Kathrin Radonić, Aleksandar Ramos Calderón, Julia Patricia Smith, Maureen Rebecca Brinkmann, Annika Trappe, Kathrin Drechsel, Oliver Klaper, Kathleen Hein, Sascha Hildt, Eberhardt Haas, Walter Calvignac-Spencer, Sébastien Semmler, Torsten Dürrwald, Ralf Thürmer, Andrea Drosten, Christian Fuchs, Stephan Kröger, Stefan von Kleist, Max Wolff, Thorsten Clin Infect Dis Precision Vaccines Supplement BACKGROUND: Comprehensive pathogen genomic surveillance represents a powerful tool to complement and advance precision vaccinology. The emergence of the Alpha variant in December 2020 and the resulting efforts to track the spread of this and other severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern led to an expansion of genomic sequencing activities in Germany. METHODS: At Robert Koch Institute (RKI), the German National Institute of Public Health, we established the Integrated Molecular Surveillance for SARS-CoV-2 (IMS-SC2) network to perform SARS-CoV-2 genomic surveillance at the national scale, SARS-CoV-2–positive samples from laboratories distributed across Germany regularly undergo whole-genome sequencing at RKI. RESULTS: We report analyses of 3623 SARS-CoV-2 genomes collected between December 2020 and December 2021, of which 3282 were randomly sampled. All variants of concern were identified in the sequenced sample set, at ratios equivalent to those in the 100-fold larger German GISAID sequence dataset from the same time period. Phylogenetic analysis confirmed variant assignments. Multiple mutations of concern emerged during the observation period. To model vaccine effectiveness in vitro, we employed authentic-virus neutralization assays, confirming that both the Beta and Zeta variants are capable of immune evasion. The IMS-SC2 sequence dataset facilitated an estimate of the SARS-CoV-2 incidence based on genetic evolution rates. Together with modeled vaccine efficacies, Delta-specific incidence estimation indicated that the German vaccination campaign contributed substantially to a deceleration of the nascent German Delta wave. CONCLUSIONS: SARS-CoV-2 molecular and genomic surveillance may inform public health policies including vaccination strategies and enable a proactive approach to controlling coronavirus disease 2019 spread as the virus evolves. Oxford University Press 2022-06-25 /pmc/articles/PMC9278222/ /pubmed/35749674 http://dx.doi.org/10.1093/cid/ciac399 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Precision Vaccines Supplement Oh, Djin Ye Hölzer, Martin Paraskevopoulou, Sofia Trofimova, Maria Hartkopf, Felix Budt, Matthias Wedde, Marianne Richard, Hugues Haldemann, Berit Domaszewska, Teresa Reiche, Janine Keeren, Kathrin Radonić, Aleksandar Ramos Calderón, Julia Patricia Smith, Maureen Rebecca Brinkmann, Annika Trappe, Kathrin Drechsel, Oliver Klaper, Kathleen Hein, Sascha Hildt, Eberhardt Haas, Walter Calvignac-Spencer, Sébastien Semmler, Torsten Dürrwald, Ralf Thürmer, Andrea Drosten, Christian Fuchs, Stephan Kröger, Stefan von Kleist, Max Wolff, Thorsten Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) |
title | Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) |
title_full | Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) |
title_fullStr | Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) |
title_full_unstemmed | Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) |
title_short | Advancing Precision Vaccinology by Molecular and Genomic Surveillance of Severe Acute Respiratory Syndrome Coronavirus 2 in Germany, 2021( ) |
title_sort | advancing precision vaccinology by molecular and genomic surveillance of severe acute respiratory syndrome coronavirus 2 in germany, 2021( ) |
topic | Precision Vaccines Supplement |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278222/ https://www.ncbi.nlm.nih.gov/pubmed/35749674 http://dx.doi.org/10.1093/cid/ciac399 |
work_keys_str_mv | AT ohdjinye advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT holzermartin advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT paraskevopoulousofia advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT trofimovamaria advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT hartkopffelix advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT budtmatthias advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT weddemarianne advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT richardhugues advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT haldemannberit advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT domaszewskateresa advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT reichejanine advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT keerenkathrin advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT radonicaleksandar advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT ramoscalderonjuliapatricia advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT smithmaureenrebecca advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT brinkmannannika advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT trappekathrin advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT drechseloliver advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT klaperkathleen advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT heinsascha advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT hildteberhardt advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT haaswalter advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT calvignacspencersebastien advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT semmlertorsten advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT durrwaldralf advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT thurmerandrea advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT drostenchristian advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT fuchsstephan advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT krogerstefan advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT vonkleistmax advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT wolffthorsten advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 AT advancingprecisionvaccinologybymolecularandgenomicsurveillanceofsevereacuterespiratorysyndromecoronavirus2ingermany2021 |